Bayer ’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement (for specialized target groups only)

Positive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent placement (1) / PIONEER AF-PCI is the first and currently only randomised clinical trial of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Final decision of European Commission expected by the end of this year
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news